Stockreport

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]

Astria Therapeutics, Inc.  (ATXS) 
PDF -- Final 3- and 6-Month Results from the ALPHA-STAR Trial of Navenibart Expected in Q4 2024 -- -- STAR-0310 Investigational New Drug (IND) Application Submission On-T [Read more]